<DOC>
	<DOCNO>NCT01649960</DOCNO>
	<brief_summary>The investigator study two phase . The first phase pilot study 18 participant [ patient 60 year old coronary artery disease ( CAD ) undergo percutaneous coronary intervention ( PCI ) coronary artery bypass surgery ( CABG ) patient eligible undergo participate cardiac rehabilitation ( CR ) ] ; 6 participant give oral daily rapamycin ( 0.5 , 1 , 2mg ) dose duration CR . Baseline follow-up data collect age-associated impairment ( AAI ) : frailty ( primary endpoint ) quality life ( QOL ) , senescent-associated secretory phenotype ( SASP ) abdominal/thigh subcutaneous adipose biopsy measurement adipocyte mitochondrial DNA copy number quantitate number senescent preadipocytes . Safety rapamycin assess periodic clinical follow-up , blood draw , serum rapamycin level . Following completion pilot phase , data analyze . If favorable change note SASP AAI , investigator start phase 2 randomized trial . Second phase : In prospective , randomize , clinical trial design , patient 60 year old randomized time CR standardize exercise protocol , exercise protocol addition low-dose rapamycin test hypothesis whether low-dose rapamycin ( demonstrate pilot trial improve SASP/AAI ) improve measure AAI , SASP , finding fat biopsy compare exercise alone . The null hypothesis improvement rapamycin measure AAI SASP .</brief_summary>
	<brief_title>Exercise Low-Dose Rapamycin Older Adults With CAD : Cardiac Rehabilitation And Rapamycin Elderly ( CARE ) Trial</brief_title>
	<detailed_description>Participants : Pilot study : Patients , 60 year old , select single-center open label pilot study consent participation initiation CR follow PCI CABG . We enroll 18 patient ; 6 patient receive dose one three propose levels:0.5mg , 1.0mg , 2mg daily oral rapamycin duration CR ( typically 12 week ) . We perform physical performance test frailty assessment , short-form 12 quality life , test SASP [ ( IL-6 ) , matrix metalloproteinase ( MMP ) 3 , monocyte chemotactic protein ( MCP ) 1 ] , abdominal/thigh subcutaneous adipose biopsy measurement adipocyte mitochondrial DNA copy number quantitate number senescent preadipocytes . baseline conclusion CR . Fasting lipid panel perform baseline completion CR . Baseline complete blood count , liver , kidney function perform . These test repeat 14 day , 30 day , 8 week , completion CR . Serum rapamycin level measure 7 , 14 , 30 day , completion CR . The serum level drug keep 6ng/ml . If drug level find higher , next low dose medication prescribe . Participants serious side effect ( appendix ) medication withdraw study . Patients enrol set three . Thirty day monitor must pass three subject three may enrol . The first three patient assign 0.5 mg dose level . If two patient three serious adverse event , pilot study terminate . If 1 3 patient serious adverse event , enroll three subject 0.5 mg level . If three serious event event first three subject , proceed enroll three subject 1.0mg level . Otherwise , 2 serious event 6 patient assign 0.5mg , terminate study . We proceed similarly 1.0 mg level enrol patient 2.0 mg level . If observe 2 serious event 1.0 mg level 3 patient enrol 0.5mg level , finish pilot enrol 3 0.5 mg level . Similarly , observe 2 serious event 2.0 mg level 3 subject ( 0 event ) 1.0 level , enroll 3 1.0 level . Randomized Trial : The Cardiac rehabilitation And Rapamycin Elderly ( CARE ) study prospective , randomize , phase 2 clinical trial do Mayo Clinic , Rochester , MN . The pool potential study participant consist patient 60 year old CAD refer CR follow PCI CABG . To minimize drop rate , obtain consent end first week CR participation , since patient quit CR first week . Consent obtain study coordinator . Baseline Assessment : Following informed consent , assessment height , weight , blood pressure make , participant chemistry 15 panel , complete blood cell count , electrocardiogram . Race ethnicity self-reported . Baseline demographic , angiographic , relevant clinical laboratory data enter prospectively database . Biochemical parameter : The mechanism rapamycin retard cellular senescence extend life span still unclear . With aim , good understanding effect rapamycin inflammation , mitochondrial DNA copy number , quantitation senescent preadipocytes diverse biomarkers age could demonstrate . To assess effect CR , ass parameter baseline completion CR program . SASP : Proinflammatory biomarkers , IL-6 , MMP 3 MCP 1 study ( ELISA ) . Patients randomize 1:1 ratio either regular CR , CR addition 0.5mg/1.0mg/2.0mg rapamycin . The low dose rapamycin demonstrate potential reduce SASP , and/or improve AAI pilot trial use . Inclusion Criteria 1 . Age 60 year old 2 . Patients eligible CR . 3 . Informed write consent . Exclusion criteria 1 . Class III IV CHF . 2 . Creatinine &gt; 2.0 mg/dl . 3 . HbA1c &gt; 13 % . 4 . Any malignancy 5 . Hematological disorder , include thrombocytopenia , leucopenia . 6 . Noncardiac illness expect limit survival . 7 . Chronic liver disease . 8 . Suspected known pregnancy . 9 . Geographically inaccessible unable return follow-up . 10 . Unable understand cooperate protocol requirement . 12 . Post organ transplant immune-compromised status 13 . Prior stroke disability , severe Parkinson disease 14 . Dementia 15 . Post-CABG &lt; 3 month evidence active wound ulcer . 16.Anticipating elective surgery 3 month follow enrollment .</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria 1 . Age 60 year old 2 . Patients eligible undergo cardiac rehabilitation . 3 . Informed write consent . Exclusion criteria 1 . Class III IV CHF . 2 . Creatinine &gt; 2.0 mg/dl . 3 . HbA1c &gt; 13 % . 4 . Any malignancy 5 . Hematological disorder , include thrombocytopenia , leucopenia . 6 . Noncardiac illness expect limit survival . 7 . Chronic liver disease . 8 . Suspected known pregnancy . 9 . Geographically inaccessible unable return followup . 10 . Unable understand cooperate protocol requirement . 11 . Post organ transplant immunecompromised status 12 . Prior stroke disability , severe Parkinson disease 13 . Dementia 14 . PostCABG &lt; 3 month evidence active wound ulcer . 15 . Anticipating elective surgery 3 month follow enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Aging</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>CAD</keyword>
</DOC>